Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: HSP90AA1

Summary for HSP90AA1

Gene information	Gene symbol	HSP90AA1
	Ensembl ID	ENSG00000080824
	Entrez ID	3320
	Gene name	heat shock protein 90 alpha family class A member 1
	Synonyms	FLJ31884\|Hsp89\|Hsp90\|HSP90N\|HSPC1\|HSPCA
	Gene type	protein_coding
	UniProtAcc	P07900

Top

Dataset with differentially expressed gene: HSP90AA1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-1.18365	2.55e-26
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	0.427237	4.77e-26
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.328249	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.738461	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.849082	1.20e-29
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.711125	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.785178	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.996199	9.49e-17
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.459783	1.88e-30
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	1.24079	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.548683	2.35e-13
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.512907	3.34e-42
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.51404	1.35e-04
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.37193	1.45e-25
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.293749	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.27618	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	pDCs	-1.30503	1.32e-02
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Plasma cells	-0.999004	2.65e-07
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.34085	2.95e-08
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.500117	1.10e-06
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.88465	5.56e-06
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.775715	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-1.7845	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.716777	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.552416	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	pDCs	-1.33671	2.91e-11
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-1.37147	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	NK cells	0.305092	1.89e-10
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.298797	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-1.63025	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.82381	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-2.60158	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.398986	3.24e-11
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	-1.12315	7.83e-04
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-0.780316	6.46e-07
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.802056	2.15e-12
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	2.11744	9.24e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	1.6533	1.45e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.936458	2.34e-11
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.392781	2.07e-11
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	1.02082	1.50e-07
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.427412	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	1.11714	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	0.960468	3.10e-11
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-1.29521	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	0.447011	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	pre	Malignant cells	0.318902	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	1.58192	0.00e+00
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	-1.08995	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	0.320874	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	0.355948	1.49e-03
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.284854	5.93e-06
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	1.03697	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.64705	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.328692	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.347195	2.74e-05
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.26074	1.02e-09
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.298426	3.48e-05
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.306491	1.25e-08
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.505044	5.39e-30
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.71311	1.63e-36
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.602649	1.19e-33
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-1.02608	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.44675	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.967671	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	-0.470632	1.83e-32
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.668423	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.534303	3.34e-42
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	-0.54436	3.66e-37
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.41317	9.58e-41
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	cDCs	-0.509763	1.88e-05
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-1.12016	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.319052	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	1.3576	0.00e+00

Top

Expression of HSP90AA1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to HSP90AA1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating HSP90AA1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
HSP90AA1	hsa-miR-6847-5p	94.4101	NM_005348
HSP90AA1	hsa-miR-5003-3p	93.8575	NM_005348
HSP90AA1	hsa-miR-5688	93.1843	NM_001017963
HSP90AA1	hsa-miR-520g-5p	93.01	NM_001017963
HSP90AA1	hsa-miR-7-1-3p	91.7865	NM_001017963
HSP90AA1	hsa-miR-495-3p	91.7865	NM_001017963
HSP90AA1	hsa-miR-7-2-3p	91.7865	NM_001017963
HSP90AA1	hsa-miR-4682	89.3002	NM_005348
HSP90AA1	hsa-miR-4742-3p	88.1054	NM_005348
HSP90AA1	hsa-miR-6502-3p	87.8252	NM_001017963
HSP90AA1	hsa-miR-361-5p	85.4893	NM_005348
HSP90AA1	hsa-miR-141-5p	83.3426	NM_005348
HSP90AA1	hsa-miR-219a-2-3p	81.7576	NM_001017963
HSP90AA1	hsa-miR-374a-3p	80.1168	NM_005348

Page: 1

Top

Motifs and transcription factors (TFs) regulating HSP90AA1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
HSP90AA1	swissregulon__hs__ELF2	ELF2 (directAnnotation).
HSP90AA1	taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP	ETV5; FOXI1 (directAnnotation).
HSP90AA1	cisbp__M02645	ETS1 (directAnnotation).
HSP90AA1	taipale_tf_pairs__FOXO1_ELK1_TGTTGCCGGANNN_CAP	ELK1; FOXO1 (directAnnotation).
HSP90AA1	taipale_tf_pairs__ETV2_TCF3_CASSTGNNCCGGAWRYN_CAP_repr	ETV2; TCF3 (directAnnotation).
HSP90AA1	jaspar__MA1483.2	ELF2 (directAnnotation).
HSP90AA1	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).
HSP90AA1	cisbp__M08198	ELF1 (directAnnotation).
HSP90AA1	taipale_cyt_meth__ZBTB2_NTTTMCGGTWAN_eDBD	ZBTB2 (directAnnotation).
HSP90AA1	taipale_tf_pairs__E2F1_HES7_RRCRCGYGYNNNNSGCGCSN_CAP_repr	E2F1; HES7 (directAnnotation).
HSP90AA1	kznf__ZFP57_Imbeault2017_RP_ChIP-seq	ZFP57 (directAnnotation).
HSP90AA1	swissregulon__hs__ZBTB14	ZBTB14 (directAnnotation).
HSP90AA1	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
HSP90AA1	transfac_pro__M04826	EP300 (directAnnotation).
HSP90AA1	taipale_tf_pairs__ETV2_HES7_NNCACGTGNNNNNCGGAWRY_CAP_repr	ETV2; HES7 (directAnnotation).
HSP90AA1	taipale_cyt_meth__E2F2_GCGCGCGCGYW_eDBD_repr	E2F2 (directAnnotation).
HSP90AA1	taipale_tf_pairs__ERF_HES7_NNCACGTGNNNNCCGGAANN_CAP_repr	ERF; HES7 (directAnnotation).
HSP90AA1	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
HSP90AA1	metacluster_56.5	HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
HSP90AA1	metacluster_21.5	HOXB2; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4 (directAnnotation). HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4; HSF4; HSF5; HSF5; HSF5; HSF5; HSFX1; HSFX1; HSFX1; HSFX1; HSFX2; HSFX2; HSFX2; HSFX2; HSFX3; HSFX3; HSFX3; HSFX3; HSFX4; HSFX4; HSFX4; HSFX4; HSFY1; HSFY1; HSFY1; HSFY1; HSFY2; HSFY2; HSFY2; HSFY2 (inferredBy_Orthology).
HSP90AA1	metacluster_56.4	HSF1; HSF2; HSF2; HSF4 (directAnnotation).
HSP90AA1	transfac_pro__M05474	ZNF639 (directAnnotation).
HSP90AA1	taipale_tf_pairs__TEAD4_GATA3_NGATAASNNNRGWATGY_CAP_repr	GATA3; TEAD4 (directAnnotation).
HSP90AA1	taipale_tf_pairs__TFAP4_DLX3_NNCAGCTGNNNNTAATKR_HT	DLX3; TFAP4 (directAnnotation).
HSP90AA1	taipale_tf_pairs__ERF_DLX2_RSCGGAANNNNNYMATTA_CAP_repr_1	DLX2; ERF (directAnnotation).
HSP90AA1	transfac_pro__M05852	ZNF689 (directAnnotation).
HSP90AA1	transfac_pro__M04856	BATF (directAnnotation).
HSP90AA1	metacluster_56.3	HSF2 (directAnnotation).
HSP90AA1	metacluster_31.7	FOXO1; FOXO3; FOXO6 (directAnnotation).
HSP90AA1	transfac_pro__M06035	ZNF749 (directAnnotation).
HSP90AA1	taipale_tf_pairs__ERF_DLX2_RSCGGAANNNNNYMATTA_CAP_repr_2	DLX2; ERF (directAnnotation).
HSP90AA1	transfac_pro__M01253	CNOT3 (directAnnotation).
HSP90AA1	transfac_pro__M00803	E2F1; E2F3; E2F4; TFDP1 (directAnnotation).
HSP90AA1	kznf__ZNF548_Imbeault2017_RP_RCADE	ZNF548 (directAnnotation).
HSP90AA1	cisbp__M01752	USF2 (inferredBy_Orthology).
HSP90AA1	tfdimers__MD00567	IKZF2 (directAnnotation).
HSP90AA1	kznf__CTCF_Rhee2011.3_ChIP-exo	CTCF (directAnnotation).
HSP90AA1	metacluster_52.13	LEF1; LEF1; LEF1; LEF1; TCF7; TCF7; TCF7L1; TCF7L1 (directAnnotation).
HSP90AA1	transfac_pro__M06564	ZNF578 (directAnnotation).
HSP90AA1	taipale_tf_pairs__GCM2_DLX2_RTRCGGGNNNNNTAATTR_CAP_repr	DLX2; GCM2 (directAnnotation).
HSP90AA1	taipale_tf_pairs__ETV2_NHLH1_NGCAGCTGCCGGAWRYN_CAP_repr	ETV2; NHLH1 (directAnnotation).
HSP90AA1	metacluster_131.3	ZNF436 (inferredBy_Orthology).
HSP90AA1	transfac_pro__M06353	ZNF782 (directAnnotation).
HSP90AA1	metacluster_7.7	SP2 (directAnnotation). KLF16 (inferredBy_Orthology).
HSP90AA1	swissregulon__hs__HSF2	HSF2 (directAnnotation).
HSP90AA1	transfac_pro__M05779	ZNF674 (directAnnotation).
HSP90AA1	transfac_pro__M05956	BCL11B (directAnnotation).
HSP90AA1	transfac_pro__M01251	E2F1 (directAnnotation).
HSP90AA1	transfac_pro__M05782	ZNF324B (directAnnotation).
HSP90AA1	taipale_tf_pairs__PBX4_HOXA10_NTCGTAAATCA_CAP_repr	HOXA10; PBX4 (directAnnotation).

Page: 1 2 3 4 5 6

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
HSP90AA1	"(3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one"	DB07317	small molecule
HSP90AA1	"(5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime"	DB08197	small molecule
HSP90AA1	"2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol"	DB08443	small molecule
HSP90AA1	"2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE"	DB08789	small molecule
HSP90AA1	"2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxa	DB06969	small molecule
HSP90AA1	"2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide"	DB08557	small molecule
HSP90AA1	"3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE"	DB08788	small molecule
HSP90AA1	"3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE"	DB07324	small molecule
HSP90AA1	"4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid"	DB02840	small molecule
HSP90AA1	"4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole"	DB03749	small molecule
HSP90AA1	"4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine"	DB08787	small molecule
HSP90AA1	"4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine"	DB08786	small molecule
HSP90AA1	"4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol"	DB07502	small molecule
HSP90AA1	"4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL"	DB07100	small molecule
HSP90AA1	"4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL"	DB06957	small molecule
HSP90AA1	"4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol"	DB07601	small molecule
HSP90AA1	"4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine"	DB08194	small molecule
HSP90AA1	"4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol"	DB08442	small molecule
HSP90AA1	"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE"	DB07495	small molecule
HSP90AA1	"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE"	DB06964	small molecule
HSP90AA1	"5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE"	DB06958	small molecule
HSP90AA1	"5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide"	DB06961	small molecule
HSP90AA1	"6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE"	DB07319	small molecule
HSP90AA1	"8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine"	DB03137	small molecule
HSP90AA1	"8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine"	DB03093	small molecule
HSP90AA1	"8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine"	DB02550	small molecule
HSP90AA1	"8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine"	DB04505	small molecule
HSP90AA1	"8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE"	DB07877	small molecule
HSP90AA1	"8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine"	DB04254	small molecule
HSP90AA1	"8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-"	DB08436	small molecule
HSP90AA1	"9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine"	DB04054	small molecule
HSP90AA1	"9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine"	DB02359	small molecule
HSP90AA1	"9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine"	DB03504	small molecule
HSP90AA1	"9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine"	DB02754	small molecule
HSP90AA1	"9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine"	DB03809	small molecule
HSP90AA1	"9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine"	DB03899	small molecule
HSP90AA1	"Alvespimycin"	DB12442	small molecule
HSP90AA1	"CCT-018159"	DB07594	small molecule
HSP90AA1	"Copper"	DB09130	small molecule
HSP90AA1	"Geldanamycin"	DB02424	small molecule
HSP90AA1	"N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE"	DB06956	small molecule
HSP90AA1	"N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BE	DB07325	small molecule
HSP90AA1	"N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE"	DB04588	small molecule
HSP90AA1	"Nedocromil"	DB00716	small molecule
HSP90AA1	"Polaprezinc"	DB09221	small molecule
HSP90AA1	"Quercetin"	DB04216	small molecule
HSP90AA1	"Rifabutin"	DB00615	small molecule
HSP90AA1	"SNX-5422"	DB06070	small molecule
HSP90AA1	"Tanespimycin"	DB05134	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."